Search Results - cd47

4 Results Sort By:
Radioprotectants and Tumor Radiosensitizers Targeting Thrombospondin-1 and CD47
Abstract: The National Cancer Institute''s Laboratory of Pathology is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize CD47-targeting agents as radioprotectants and tumor sensitizers. Radiation therapy not only damages cancer cells, but it also damages healthy...
Published: 4/8/2024   |   Inventor(s): David Roberts, Justin Maxhimer, Jeff Isenberg
Keywords(s): CANCER, CD47, Morpholinos, Radioprotective Agents, Radiotherapeutics, Thrombospondin-1 (TSP1), Tumor Sensitizers
Category(s): Collaboration Sought > Licensing
Modulating Chemotherapeutic Cytotoxicity
Abstract: Many chemotherapeutic agents cause significant cytotoxicity to non-cancer ("normal") cells, resulting in undesirable side-effects and often limiting the dose and/or duration of chemotherapy that can be administered to a patient. Investigators at the National Cancer Institute’s Laboratory of Pathology have demonstrated that deficiency or blockade...
Published: 4/8/2024   |   Inventor(s): David Roberts, David Soto Pantoja
Keywords(s): CD47, morpholino
Category(s): Application > Therapeutics, Collaboration Sought > Licensing, Collaboration Sought > Collaboration, TherapeuticArea > Oncology
Use of Anti-CD47 Antibodies for the Treatment of Cancer
Abstract: High expression of CD47, a cell surface receptor on several types of cancer cells, has been identified as a ‘don’t eat me signal’ that inhibits their killing by macrophages or NK cells. Conversely, the CD47 antibody B6H12 that blocks SIRPα binding enhances macrophage-dependent clearance of tumors in several mouse models, although others have...
Published: 4/8/2024   |   Inventor(s): David Roberts, Sukhbir Kaur, Chengyu Liu
Keywords(s): CD47, Stem Cell
Category(s): Collaboration Sought > Licensing, Application > Therapeutics, Collaboration Sought > Collaboration, TherapeuticArea > Oncology
Methods of preventing tissue ischemia
Abstract: The National Cancer Institute's Laboratory of Pathology is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize therapeutics targeting vasodialation. Nitric oxide (NO) plays an important role as a major intrinsic vasodilator, and increases blood flow...
Published: 4/8/2024   |   Inventor(s): Jeff Isenberg, David Roberts, William Frazier
Keywords(s): CD47, ISCHEMIA, nitric oxide, NO, THROMBOSPONDIN
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics